Indegene Limited

NSE INDGN.NS

Indegene Limited EBIT for the year ending March 31, 2024: USD 52.12 M

Indegene Limited EBIT is USD 52.12 M for the year ending March 31, 2024, a 8.61% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.
  • Indegene Limited EBIT for the year ending March 31, 2023 was USD 47.98 M, a 56.73% change year over year.
  • Indegene Limited EBIT for the year ending March 31, 2022 was USD 30.61 M, a -0.70% change year over year.
  • Indegene Limited EBIT for the year ending March 31, 2021 was USD 30.83 M, a 85.87% change year over year.
  • Indegene Limited EBIT for the year ending March 31, 2020 was USD 16.59 M.
Key data
Date EBIT EBITDA Net Income EPS (Diluted)
Market news
NSE: INDGN.NS

Indegene Limited

CEO Mr. Manish Gupta BTech, MBA
IPO Date May 13, 2024
Location India
Headquarters Manyata Embassy Business Park
Employees 4,367
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Indegene Limited operates as a life sciences commercialization company in India and internationally. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get to the market, and grow impact through the life cycle. The company offers enterprise commercial solutions, enterprise medical solutions, enterprise clinical solutions, omnichannel activation solutions, and NEXT technology platforms. The company was incorporated in 1998 and is based in Bengaluru, India.

StockViz Staff

January 15, 2025

Any question? Send us an email